Mesenchymal stem cells and immunomodulation: current status and future prospects.

Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Tse HF, Fu QL, Lian Q. · 2016

Read Mesenchymal stem cells and immunomodulation: current status and future prospects. by Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Tse HF, Fu QL, Lian Q. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4816164.txt.

Introduction

F. Gao and eight co-authors review mesenchymal stem cells as immune calmers in Cell Death & Disease in 2016. These stem cells, drawn from marrow, fat, and cord tissue, can mute an overactive immune system: they stall attacking T cells, soften inflammation signals, and coax regulatory cells up. That talent has made them candidates for graft-versus-host disease, lupus, and other immune disorders.

The review sums the state of the field: the signals the cells release, the immune cell types they touch, and the trial record so far. It also faces the gaps. Cell batches vary by source and handling, dosing is unsettled, and manufacturing standards are still forming. The authors set out what must be standardized before these cells can move from promising trials to routine therapy.

Catalog record

CREATORGao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Tse HF, Fu QL, Lian Q.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4816164

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mesenchymal stem cells and immunomodulation: current status and future prospects By F Gao, S M Chiu, D A L Motan, Z Zhang, L Chen, H-L Ji, H-F Tse, Q-L Fu, Q Lian Published in: Cell Death & Disease DOI: 10.1038/cddis.2015.327 ABSTRACT Abstract GLOSSARY BMbone marrowiPSCinduced pluripotent stem cellCCR7cytokine receptor 7iNOSinducible nitric oxide synthaseCOX2cyclooxygenase 2MSCmesenchymal stem cellGMPgood manufacturing practicesNKnatural killer cellGvHDgraft versus host diseasesNOnitric oxidehESChuman embryonic stem cellOVAovalbuminHGFhepatocyte growth factorPGE2prostaglandin E2HLAhuman leukocyte antigenSLEsystemic lupus erythematosusIDOindoleamine 2, 3-dioxygenaseTGF-βtransforming growth factor-βIFN-γinterferon-γTNF-αtumor necrosis factor-αIL-10interleukin-10Tregregulatory T cell The authors declare no conflict of interest. FOOTNOTES Edited by H-U Simon REFERENCES Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36: 2566–2573.Siegel G, Schafer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 2009; 87(9 Suppl): S45–S49.Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129: 118–129.Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007; 28: 219–226.Sehmi R, Baatjes AJ, Denburg JA. Hemopoietic progenitor cells and hemopoietic factors: potential targets for treatment of allergic inflammatory diseases. Curr Drug Targets Inflamm Allergy 2003; 2: 271–278.Denburg JA, Inman MD, Wood L, Ellis R, Sehmi R, Dahlback M et al. Bone marrow progenitors in allergic airways diseases: studies in canine and human models. Int Arch Allergy Immunol 1997; 113: 181–183.Sehmi R, Denburg JA. Haemopoietic mechanisms in allergic rhinitis. Clin Exp Allergy 2005; 35: 1–3.Denburg JA, Inman MD, Sehmi R, Uno M, O'Byrne PM. Hemopoietic mechanisms in allergic airway inflammation. Int Arch Allergy Immunol 1998; 117: 155–159.Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582–2591.Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821–2827.Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212–222.Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367–372.Burchell JT, Strickland DH, Stumbles PA. The role of dendritic cells and regulatory T cells in the regulation of allergic asthma. Pharmacol Ther 2010; 125: 1–10.Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71–76.Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484–1490.Trivedi P, Hematti P. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol 2008; 36: 350–359.Yen BL, Chang CJ, Liu KJ, Chen YC, Hu HI, Bai CH et al. Brief report—human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells 2009; 27: 451–456.Tan Z, Su ZY, Wu RR, Gu B, Liu YK, Zhao XL et al. Immunomodulative effects of mesenchymal stem cells derived from human embryonic stem cells in vivo and in vitro. J Zhejiang Univ Sci B 2011; 12: 18–27.Fu QL, Chow YY, Sun SJ, Zeng QX, Li HB, Shi JB et al. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. Allergy 2012; 67: 1215–1222.Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441.Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009; 182: 5994–6002.Cho KS, Park HK, Park HY, Jung JS, Jeon SG, Kim YK et al. IFATS collection: immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells 2009; 27: 259–265.Cho KS, Roh HJ. Immunomodulatory effects of adipose-derived stem cells in airway allergic diseases. Curr Stem Cell Res Ther 2010; 5: 111–115.Goodwin M, Sueblinvong V, Eisenhauer P, Ziats NP, LeClair L, Poynter ME et al. Bone marrow-derived mesenchymal stromal cells inhibit Th2-mediated allergic airways inflammation in mice. Stem Cells 2011; 29: 1137–1148.Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652–5657.Bonfield TL, Koloze M, Lennon DP, Zuchowski B, Yang SE, Caplan AI. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol 2010; 299: L760–L770.Bonfield TL, Nolan Koloze MT, Lennon DP, Caplan AI. Defining human mesenchymal stem cell efficacy in vivo. J Inflamm 2010; 7: 51.Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, Stubbs AP et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010; 162: 474–486.Raicevic G, Najar M, Najimi M, El Taghdouini A, van Grunsven LA, Sokal E et al. Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells. Cytotherapy 2015; 17: 174–185.Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010; 184: 2321–2328.Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010; 19: 667–679.Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110: 3691–3694.Sun YQ, Deng MX, He J, Zeng QX, Wen W, Wong DS et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells 2012; 30: 2692–2699.Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386–398.Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353–363.DelaRosa O, Lombardo E, Beraza A, Mancheno-Corvo P, Ramirez C, Menta R et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 2009; 15: 2795–2806.Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2:

Read the complete text